YONGZHONG WEI: Open Payments
NPI 1720227143 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$811 in 33 payments from 10 companies in 2025. Trend: 2023 $2,207 · 2024 $2,166 · 2025 $811
Food & beverage: $661Consulting: $150
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $276 |
| Biogen, Inc. | 6 | $247 |
| TG Therapeutics, Inc. | 3 | $69 |
| ABBVIE INC. | 2 | $54 |
| EMD Serono, Inc. | 2 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Amgen Inc. | 1 | $20 |
| ACADIA Pharmaceuticals Inc | 1 | $20 |
| Alexion Pharmaceuticals, Inc. | 1 | $16 |
| PFIZER INC. | 1 | $14 |
Products named: KESIMPTA, TYSABRI, BRIUMVI, QULIPTA, AUSTEDO XR, UPLIZNA, NUPLAZID, ULTOMIRIS.
Industry payments across MO — which companies pay providers there.
